Table 2.
Fully adjusted linear regressions examining the association between use of vitamin K antagonists and cognitive scores at baseline.
| Cognitive Scores | ||||||
|---|---|---|---|---|---|---|
| MMSE Score (n = 378) | FAB Score (n = 253) | |||||
| β | [95% CI] | p-Value | β | [95% CI] | p-Value | |
| Use of vitamin K antagonists | 0.51 | [−2.38, 23.26] | 0.655 | −2.12 | [−3.99, −0.25] | 0.026 |
| Age | 0.05 | [−1.75, 2.77] | 0.443 | 0.02 | [−0.07, 0.11] | 0.635 |
| Female gender | 0.80 | [−0.07, 0.16] | 0.228 | 0.59 | [−0.40, 1.59] | 0.242 |
| Body mass index | 0.19 | [0.04, 0.34] | 0.011 | −0.03 | [−0.15, 0.09] | 0.649 |
| Mean arterial pressure | −0.01 | [−0.06, 0.03] | 0.564 | 0.002 | [−0.04, 0.04] | 0.939 |
| Number of comorbidities | 0.08 | [−0.20, 0.35] | 0.578 | −0.03 | [−0.25, 0.20] | 0.823 |
| Disability * | −2.95 | [−4.35, −1.55] | <0.001 | −0.46 | [−1.52, 0.60] | 0.393 |
| Gait Speed | 0.07 | [0.04, 0.10] | <0.001 | 0.05 | [0.03, 0.07] | <0.001 |
| Atrial fibrillation | −0.38 | [−2.46, 1.71] | 0.722 | 1.12 | [−0.67, 2.92] | 0.219 |
| Stroke | 0.60 | [−1.46, 2.66] | 0.566 | 1.03 | [−0.64, 2.69] | 0.225 |
| ARWMC score | −0.04 | [−0.60, 0.53] | 0.897 | −0.35 | [−0.80, 0.09] | 0.115 |
| Carotid artery stenosis | −1.59 | [−3.91, 0.73] | 0.178 | −0.79 | [−2.63, 1.06] | 0.402 |
| Use of psychoactive drugs | −0.08 | [−1.27, 1.11] | 0.898 | −0.66 | [−1.57, 0.25] | 0.156 |
| Use of antidementia drugs | −3.63 | [−4.79, −2.48] | <0.001 | −1.57 | [−2.47, −0.67] | 0.001 |
| Creatinine concentration | −0.001 | [−0.02, 0.02] | 0.961 | −0.001 | [−0.02, 0.02] | 0.915 |
| Vitamin B12 concentration | 0.00 | [−0.00, 0.00] | 0.830 | 0.00 | [−0.00, 0.00] | 0.836 |
| Use of antiplatelet medications | 1.07 | [−0.24, 2.38] | 0.109 | 0.02 | [−1.01, 1.06] | 0.963 |
β: coefficient of regression corresponding to changes in cognitive score; CI: confidence interval; FAB: Frontal Assessment Battery; MMSE: Mini-Mental State Examination; *: instrumental activities of daily living score (/4) of 2 or lower.